Molecular therapy for TIIDM and obesity-associated metabolic deficits: Rivaroxaban (Trade name: Xarelto), an anti-coagulant and a blood thinner, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 8/September/2017, 12.32 pm
Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by bone-derived lipocalin 2.” This research paper, was published in the 8 March 2017 issue of the journal “Nature” [One of the best research journals […]
Molecular therapy for Metastatic cancers: Ivermectin, the anthelmintic drug, increases the expression GRHL3/GET1 (grainyhead like transcription factor 3) and Long ncRNA Gas5, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 8/September/2017, 12.20 am
From Significance of the study to Public health relevance: Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer patients die due to metastasis; (iv) cancer treatment causes […]
Natural product-based therapy for Cardiomyopathy: A pharmacological mixture encompassing Astaxanthin and Mangifrin (AM) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 7/September/2017, 12.27 am
Introduction: What they say A recent study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This study was published, in the 2 June 2015 issue of the journal “Nature Genetics” (the number 1 research journal in Genetics with an impact factor of 29.648), by Prof. Da-Zhi Wang & Jian […]
Natural product-derived CDK4/6 pathway blockade enhances the efficacy of Cancer immunotherapy: A pharmacological mixture encompassing Rosuvastatin, Tubastatin, Trichodermin, 17-DMAG, Cisplatin, Linalool (RTTDCL) inhibits the expression of cell cycle protein CDK4/CDK6, increases levels of T-III IFNs, inhibits the proliferation of Treg cells, decreases DNMT1 expression, inhibits the expression of a number of immune evasion molecules, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target genes, 7/September/2017,12.13 am
Introduction:What they say: A recent study from Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands has identified CMTM6 and CMTM4 as PD-L1 protein regulators. This study was published, in the 16 August 2017 issue of Nature (one of the best journals in General science with an […]
Natural product-derived therapy for heart regeneration and repair: A pharmaceutical mixture encompassing Rivaroxaban and Sulforaphane increases Agrin expression, activates Yap and ERK-mediated signaling, replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 7/September/2017, 12.05 am
Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708, USA; and Baylor College of Medicine and The Texas Heart Institute, Houston, Texas 77030, US shows that “The extracellular matrix protein Agrin promotes heart regeneration […]
Molecular therapy for muscle atrophy and wasting:Ruxolitinib (Trade name: Jakavi/Jakafi), a drug used in the treatment of Myelofibrosis, increases the expression of FGF19 and its receptor ß-Klotho, phosphorylates ERK1/2 and S6K1, decreases the expression of tumor suppressors genes, promotes regeneration of muscle cells and hypertrophy of skeletal muscle, and reverses muscular atrophy and wasting via up regulation of its target gene, 6/September/2017, 11.57 pm
Introduction: What they say A study from Department of Biology, University of Bergen, Bergen, Norway; and Univ-Lyon, CarMeN Laboratory, INSERM 1060, INRA 1397, Université Claude Bernard Lyon, INSA Lyon, Oullins, France shows that FGF19 regulates skeletal muscle mass and ameliorates muscle wasting in mice. This research paper was published, in the 26 June 2017 issue of the journal “Nature Medicine” [One of the best […]